CLINICAL TRIALS PROFILE FOR CASPOFUNGIN ACETATE

All Clinical Trials for caspofungin acetate

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00008359 ↗	Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment	Completed	National Cancer Institute (NCI)	Phase 3	2000-08-01	RATIONALE: Caspofungin acetate or amphotericin B liposomal may be effective in preventing or controlling fever and neutropenia caused by chemotherapy, bone marrow transplantation, or peripheral stem cell transplantation. It is not yet known whether caspofungin acetate or amphotericin B liposomal is more effective for treating these side effects. PURPOSE: Randomized phase III trial to compare the effectiveness of caspofungin acetate with that of amphotericin B liposomal in treating patients who have persistent fever and neutropenia after receiving anticancer therapy.
NCT00008359 ↗	Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment	Completed	Memorial Sloan Kettering Cancer Center	Phase 3	2000-08-01	RATIONALE: Caspofungin acetate or amphotericin B liposomal may be effective in preventing or controlling fever and neutropenia caused by chemotherapy, bone marrow transplantation, or peripheral stem cell transplantation. It is not yet known whether caspofungin acetate or amphotericin B liposomal is more effective for treating these side effects. PURPOSE: Randomized phase III trial to compare the effectiveness of caspofungin acetate with that of amphotericin B liposomal in treating patients who have persistent fever and neutropenia after receiving anticancer therapy.
NCT00020527 ↗	Caspofungin Acetate in Treating Children With Fever and Neutropenia	Completed	National Cancer Institute (NCI)	N/A	2001-03-01	RATIONALE: Giving caspofungin acetate may be effective in preventing or controlling fever and neutropenia caused by chemotherapy or bone marrow transplantation. PURPOSE: Clinical trial to study the effectiveness of caspofungin acetate in treating children who have fever and neutropenia caused by a weakened immune system.
NCT00082524 ↗	Documented Candida or Aspergillus Infections in Pediatric Patients (0991-043)	Completed	Merck Sharp & Dohme Corp.	Phase 2	2004-04-01	This study is an open label, noncomparative study using an investigational agent for the treatment of documented Candida or Aspergillus infections in pediatric patients (ages 3 months-17 years).
NCT00082537 ↗	MK0991 Versus Amphotericin B for Empirical Therapy in Febrile, Neutropenic Pediatric Patients (0991-044)	Completed	Merck Sharp & Dohme Corp.	Phase 2	2004-04-01	This study is a double-blind, randomized study of MK0991 versus liposomal amphotericin B in the empirical treatment of pediatric patients (ages 2 through 17 years) who have an absolute neutrophil count (ANC) below 500/microliter and who have fever despite broad antibiotic coverage. Such patients would be candidates for empirical therapy with an intravenous anti-fungal agent.
NCT00083343 ↗	Caspofungin for the Treatment of Non-blood Candida Infections (0991-045)	Completed	Merck Sharp & Dohme Corp.	Phase 2	2004-05-01	Candida is the most common fungal pathogen identified in hospitalized patients. This study will seek to enroll adult patients (18 years of age or older) with invasive Candida infections (involving deep tissues and organs). The study will not enroll patients whose only site of Candida infection was the bloodstream. Patients that fulfill all study entry criteria will receive a single daily dose of caspofungin. Caspofungin, an intravenous echinocandin antifungal agent, is already approved for the treatment of invasive candidiasis. The dosage strength and duration of caspofungin will be individualized for each patient based on disease, severity of disease and extent of infection.

Clinical Trial Conditions for caspofungin acetate

Condition Name

Condition Name for caspofungin acetate
Intervention	Trials
Fungal Infection	8
Candidiasis	4
Neutropenia	3
Aspergillosis	2

Condition MeSH

Condition MeSH for caspofungin acetate
Intervention	Trials
Mycoses	11
Candidiasis	7
Neutropenia	7
Infections	5

Clinical Trial Locations for caspofungin acetate

Trials by Country

Trials by Country for caspofungin acetate
Location	Trials
United States	77
Canada	10
Spain	5
France	2
Slovakia	2

Trials by US State

Trials by US State for caspofungin acetate
Location	Trials
Tennessee	3
New York	3
Nebraska	2
Missouri	2
Mississippi	2

Clinical Trial Progress for caspofungin acetate

Clinical Trial Phase

Clinical Trial Phase for caspofungin acetate
Clinical Trial Phase	Trials
Phase 4	1
Phase 3	9
Phase 2	8

Clinical Trial Status

Clinical Trial Status for caspofungin acetate
Clinical Trial Phase	Trials
Completed	16
Terminated	2
Not yet recruiting	1

Clinical Trial Sponsors for caspofungin acetate

Sponsor Name

Sponsor Name for caspofungin acetate
Sponsor	Trials
Merck Sharp & Dohme Corp.	11
National Cancer Institute (NCI)	5
European Organisation for Research and Treatment of Cancer - EORTC	2

Sponsor Type

Sponsor Type for caspofungin acetate
Sponsor	Trials
Other	11
Industry	11
NIH	5

Caspofungin Acetate: Clinical Trials Update and Market Forecast

Last updated: April 29, 2026

What is caspofungin acetate and where is it used commercially?

Caspofungin acetate is an echinocandin antifungal used for invasive fungal infections. It is marketed as branded Cancidas and in generic form in multiple territories. It is a mature product with a developed clinical and regulatory baseline, so market movement is driven mainly by (1) generic penetration, (2) hospital formulary decisions, and (3) substitution behavior within the echinocandin class rather than by new clinical differentiation.

Therapeutic positioning

• Drug class: Echinocandin antifungals
• Core indications (commercially established): Invasive aspergillosis and other serious invasive candidiasis indications depending on label/territory, including pediatric use under specified criteria (per local labeling).

Reference baseline

• Cancidas (caspofungin acetate) is the originator product with an established prescribing framework in the US and EU labeling. (See USPI and EMA product information sources.) [1], [2]

---

What does the current clinical trials landscape show?

Public, ongoing clinical development for caspofungin acetate is limited versus earlier years because the molecule is established and competition is strong. Clinical activity now tends to be concentrated in:

• comparative or combination regimens in special populations,
• post-authorization studies and observational work,
• pharmacokinetic (PK) work (often pediatric or special populations), and
• formulation or route work, usually in the context of generics or biosurrogates rather than major new indications.

Practical implication for investors and R&D planners

• Expect few phase-shifting “new label” programs for the active molecule itself.
• Watch instead for trials that could change standard-of-care usage patterns, such as regimen optimization versus other echinocandins or use in refractory or mixed infections.

Evidence of ongoing research activity (examples of active areas)

• Echinocandin class and caspofungin-related PK and clinical effectiveness continue to be studied in the literature, including pediatric and invasive fungal infection settings. [3], [4]
• The ongoing trial footprint for caspofungin acetate is best tracked via registries, but trial results and pipeline signaling are typically incremental rather than breakthrough. (Registry search is required for a complete live inventory.)

---

Which trials and publications most influence current clinical practice?

Because the molecule is mature, the primary “clinical update” signal comes from high-citation comparative and guideline-aligned evidence rather than frequent late-stage program starts.

Key evidence categories that continue to influence practice:

1. Comparative echinocandin effectiveness and safety syntheses (including meta-analyses and guideline updates).
2. Pediatric and special population dosing and PK/PD considerations.
3. Therapeutic drug monitoring and stewardship work (where relevant).
4. Combination therapy strategy in selected refractory cases.

Representative sources anchoring current clinical usage and dosing frameworks:

• US Prescribing Information for Cancidas includes dosing schedules and safety information for adult and pediatric use. [1]
• EU product information provides EMA label details by indication and population. [2]
• Review and clinical evidence summaries continue to support echinocandin selection frameworks and dosing considerations. [3], [4]

---

How does the market for caspofungin acetate work today?

Market structure

Caspofungin acetate competes inside a crowded echinocandin class. Market behavior is shaped by:

• Generic erosion of branded economics once exclusivity ends.
• Hospital purchasing power and tender-driven pricing.
• Antimicrobial stewardship pathways that affect length of therapy and switching from IV to step-down options.

Competitive set

The competitive “substitution cluster” generally includes:

• Micafungin
• Anidulafungin
• Other echinocandins in some markets (with caspofungin typically the older anchor molecule in many regions, subject to pricing dynamics).

Commercial consequence

• Caspofungin acetate revenue growth is typically driven less by new demand and more by relative share within echinocandins under pricing and formulary constraints.

---

What is the near-term market outlook and projection?

Base-case market view (directional)

For a mature IV antifungal like caspofungin acetate:

• Demand growth is linked to invasive fungal infection burden and hospital utilization patterns.
• Revenue growth is constrained by generic penetration and class competition.
• Margin and net revenue depend on tender wins, reimbursement, and the ability to maintain use in line with stewardship protocols.

Projection framework used

A robust projection approach for a mature generic-facing hospital drug is:

• patient population trend (invasive fungal infection incidence proxies),
• IV treatment penetration and typical length of therapy,
• price erosion rate due to generics and competitive tenders,
• share-of-use vs other echinocandins.

Projected trajectory (qualitative, action-oriented)

• Volume: stable to low growth depending on regional invasive fungal infection incidence and hospital practice.
• Revenue: slow growth or flat-to-declining in most mature markets due to pricing pressure.
• Share: sensitive to formulary access and switching behavior within the echinocandin class.

(Quantitative revenue forecasts require live market datasets by geography; none are provided in the sources cited below.)

---

What regulatory and labeling factors shape sales stability?

US and EU labeling stability

• US prescribing information defines established dosing and indication usage boundaries. [1]
• EU product information provides label details by indication and population. [2]

Why this matters

• Label stability supports predictable hospital protocols.
• It reduces the probability of disruptive utilization shifts unless guidelines or comparative trial evidence changes.

---

What are the biggest risks to market performance?

1. Further price compression from generic competition and tender cycles.
2. Formulary substitution toward other echinocandins with favorable dosing convenience, safety perceptions, or contracting terms.
3. Stewardship and guideline updates that change first-line selection dynamics.
4. Supply and manufacturing economics for generics, which can drive short-term pricing volatility.

---

Key Takeaways

• Caspofungin acetate is a mature, label-defined echinocandin with ongoing but generally incremental clinical activity rather than major phase-shifting development. [1], [2], [3], [4]
• Market performance is driven primarily by generic pricing, hospital formulary access, and echinocandin class substitution, not by new indication wins.
• Near-term outlook is typically stable volume with constrained revenue growth in mature markets due to competitive tender dynamics.

---

FAQs

1) Is caspofungin acetate still actively studied in clinical settings?
Yes. Research continues in areas like invasive fungal infection management, dosing considerations, and evidence syntheses, though it is largely incremental for an established molecule. [3], [4]

2) What does the Cancidas label define that matters for use?
The US prescribing information specifies dosing, indication scope, and safety framework for adult and pediatric patients. [1]

3) How does caspofungin acetate compete in practice?
It competes within the echinocandin class, where formulary access and tender pricing drive share, with Micafungin and Anidulafungin as the key substitution alternatives in many systems.

4) What is the main market risk for a mature caspofungin acetate?
Ongoing price erosion from generic competition and contracting decisions that favor lower-cost echinocandins.

5) What would most likely change the usage pattern?
Guideline or evidence updates that shift first-line echinocandin selection or recommend regimen changes for specific infection categories.

---

References (APA)

[1] U.S. Food and Drug Administration. (n.d.). Cancidas (caspofungin acetate) prescribing information.
[2] European Medicines Agency. (n.d.). Cancidas: EPAR and product information (caspofungin).
[3] World Health Organization. (n.d.). Guidance and updates on invasive fungal infection management and antifungal use (where applicable).
[4] Clinical literature on echinocandin efficacy and dosing in invasive fungal infections (systematic reviews and guideline-aligned evidence).